Elevated plasma thymopoietin associated with therapeutic nonresponsiveness in major depression

Biological Psychiatry

Volumn 48, Issue 1, 2000, Pages 65-69

  Goldstein, Gideon ^a   Fava, Maurizio ^b   Culler, Michael ^c   Fisher, Alan ^d   Rickels, Karl ^e   Lydiard, R Bruce ^f   Rosenbaum, Jerrold ^b  

^a Ortho Biotech Clinical Affairs   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c Biomeasure Inc   (United States)

^d R W JOHNSON PHARMACEUTICAL RES I   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Major depression; Plasma arginine vasopressin; Plasma thymopoietin; Pulsatile secretion; Stress; Therapeutic response

Indexed keywords

ANTIDEPRESSANT AGENT; ARGIPRESSIN; CORTICOTROPIN; FLUOXETINE; HYDROCORTISONE; NORTRIPTYLINE; THYMOPOIETIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOTROPIN BLOOD LEVEL; DEPRESSION; DRUG RESPONSE; FEMALE; HORMONE BLOOD LEVEL; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; MALE; PRIORITY JOURNAL; PULSATILE HORMONE RELEASE; STRESS;

ADRENOCORTICOTROPIC HORMONE; ADULT; ANALYSIS OF VARIANCE; ANTIDEPRESSIVE AGENTS; ARGININE VASOPRESSIN; CASE-CONTROL STUDIES; DEPRESSIVE DISORDER, MAJOR; DRUG TOLERANCE; FEMALE; HUMANS; HYDROCORTISONE; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; SEVERITY OF ILLNESS INDEX; THYMOPOIETINS;

EID: 0034237382     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-3223(00)00246-8     Document Type: Article

References (27)

1. Adusumalli V., Corkum N., Jacala A., Mukherjee T., Goodlett D., Crowther J., et al. Pharmacokinetics and toxokinetics of an orally active tripeptide, IRI-695, in animals. Biopharm Drug Dispos. 17:1996;25-41.
2. Alsheimer M., Fecher E., Benavente R. Nuclear envelope remodeling during rat spermatogenesis Distribution and expression of LAP2/thymopoietins . J Cell Sci. 111:1998;2227-2234.
3. Berger R., Theodor L., Shoham J., Gokkel E., Brok-Simoni F., Avraham K.B., et al. The characterization and localization of the mouse thymopoietin/lamina-associated polypeptide 2 gene and its alternatively spliced products. Genome Res. 6:1996;361-370.
4. Carroll B.J., Curtis G.C., Davies B.M., Mendels J., Sugerman A.A. Urinary free cortisol excretion in depression. Psychol Med. 6:1976;43-50.
5. De Bellis M.D., Gold P.W., Geracioti T.D., Listwak S.J., Kling M.A. Association of fluoxetine treatment with reductions in CSF concentrations of corticotropin-releasing hormone and arginine vasopressin in patients with major depression. Am J Psychiatry. 150:1993;656-657.
6. Deuschle M., Schweiger U., Weber B., Gotthardt U., Korner A., Schmider J., et al. Diurnal activity and pulsatility of hypothalamus-pituitary-adrenal system in male depressed patients and healthy controls. J Clin Endocrinol Metab. 82:1997;234-238.
7. Fava M., Davidson K.G. Definition and epidemiology of treatment-resistant depression. Psychiatr Clin North Am. 19:1996;179-200.
8. Fava M., Rosenbaum J.F., McGrath P.J., Stewart J.W., Amsterdam J.D., Quitkin F.M. Lithium and tricyclic augmentation of fluoxetine treatment for resistant major depression A double-blind, controlled study . Am J Psychiatry. 151:1994;1372-1374.
9. Goldstein G, Culler MD, inventors; Thymon, L.L.C., assignee (1997, January 14): Method of measuring thymopoietin proteins in plasma and serum including acidification of the plasma and serum. US patent 5,593,842.
10. Goldstein G., Scheid M.P., Boyse E.A., Schlesinger D.H., Van Wauwe J.A. A synthetic pentapeptide with biological activity characteristic of the thymic hormone thymopoietin. Science. 204:1979;1309-1310.
11. Harris C.A., Andryuk P.J., Cline S., Chan H.K., Natarajan A., Siekierka J.J., Goldstein G. Three distinct human thymopoietins are derived from alternatively spliced mRNAs. Proc Nat Acad Sci U S A. 91:1994;6283-6287.
12. Harris C.A., Andryuk P.J., Cline S.W., Mathew S., Siekierka J.J., Goldstein G. Structure and mapping of the human thymopoietin (TMPO) gene and relationship of TMPO beta to rat lamina-associated polypeptide 2. Genomics. 28:1995;198-205.
13. Heim C., Owens M.J., Plotsky P.M., Nemeroff C.B. I. Endocrine factors in the pathology of mental disorders. Persistent changes in corticotropin-releasing factor systems due to early life stress Relationship to the pathophysiology of major depression and post-traumatic stress disorder . Psychopharmacol Bull. 33:1997;185-192.
14. Keller M.B., Harrison W., Fawcett J.A., Gelenberg A., Hirschfeld R.M., Klein D., et al. Treatment of chronic depression with sertraline or imipramine preliminary blinded response rates and high rates of undertreatment in the community . Psychopharmacol Bull. 31:1995;205-212.
15. Kessler R.C., McGonagle K.A., Zhao S., Nelson C.B., Hughes M., Eshleman S., et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Arch Gen Psychiatry. 51:1994;8-19.
16. Klusa V., Kiivet R.-A., Muceniece R., Liepa I., Harro J., Svirskis S., et al. Thymopentin antagonizes stress-induced changes of GABA/benzodiazepine receptor complex. Regul Pept. 27:1990;355-365.
17. Koob G.F., Heinrichs S.C., Pich E.M., Menzaghi F., Baldwin H., Miczek K., Britton K.T. The role of corticotropin-releasing factor in behavioral responses to stress. Ciba Found Symp. 172:1993;277-289.
18. Lopez A.D., Murray C.J.L. The global burden of disease 1990-2020. Nat Med. 4:1998;1241-1243.
19. Menzaghi F., Heinrichs S.C., Vargas-Cortes M., Goldstein G., Koob G.F. IRI-514, a synthetic peptide analogue of thymopentin, reduces the behavioral response to social stress in rats. Physiol Behav. 60:1996;397-401.
20. Nicholson W.E., Davis D.R., Sherrell B.J., Orth D.N. Rapid radioimmunoassay for corticotropin in unextracted human plasma. Clin Chem. 30:1984;259-265.
21. Owens M.J., Nemeroff C.B. The role of corticotropin-releasing factor in the pathology of affective and anxiety disorder Laboratory and clinical studies . Ciba Found Symp. 172:1993;296-316.
22. Plotsky P.M., Sutton S.W., Bruhn T.O., Ferguson A.V. Analysis of the role of angiotensin II in mediation of adrenocorticotropin secretion. Endocrinology. 122:1988;538-545.
23. Redekopp C., Irvine C.H., Donald R.A., Livesey J.H., Sadler W., Nicholls M.G., et al. Spontaneous and stimulated adrenocorticotropin and vasopressin pusatile secretion in the pituitary venous effluent of the horse. Endocrinology. 118:1986;1410-1416.
24. van Londen L., Goekop J.G., van Kempen G.M.J., Frankhuijzen-Sierevogel A.C., Wiegant V.M., van der Velde E.A., De Wied D. Plasma levels of arginine vasopressin elevated in patients with major depression. Neuropsychopharmacology. 17:1997;284-292.
25. Veith R.C., Lewis N., Langohr J.I., Murburg M.M., Ashleigh E.A., Castillo S., et al. Effect of desipramine on cerebrospinal fluid concentrations of corticotropin-releasing factor in human subjects. Psychiatry Res. 46:1993;1-8.
26. Weber P.J., Eckhard C.P., Gonser S., Otto H., Folkers G., Beck-Sickinger A.G. On the role of thymopoietins in proliferation. Immunochemical evidence for new members of the thymopoietin family. Biol Chem. 380:1999;653-660.
27. Wood C.M., Butler R.J., Penney M.D., Holland P.C. Pulsatile release of arginine vasopressin (AVP) and its effect on response to desmopressin in enuresis. Scand J Urol Nephrol Suppl. 163:1994;93-101.